Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Necdet B Gunsoy

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2017
Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic AsthmaNecdet B Gunsoy, Sarah M Cockle, Steven W Yancey, et al.
Respiratory Medicine|February 1, 2017
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparisonSarah M Cockle, Gillian Stynes, Necdet B Gunsoy, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 8, 2020
Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and GermanyHannah B Lewis, Melanie Schroeder, Necdet B Gunsoy, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 17, 2017
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL studyFrank C Albers, Hana Müllerová, Necdet B Gunsoy, et al.
The Lancet. Respiratory Medicine|May 15, 2016
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesHector G Ortega, Steven W Yancey, Bhabita Mayer, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2016
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthmaSteven W Yancey, Hector G Ortega, Oliver N Keene, et al.
Pharmacoeconomics|July 25, 2023
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical RecommendationsKumar Mukherjee, Necdet B Gunsoy, Rita M Kristy, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2017
Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic AsthmaNecdet B Gunsoy, Sarah M Cockle, Steven W Yancey, et al.
Respiratory Medicine|February 1, 2017
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparisonSarah M Cockle, Gillian Stynes, Necdet B Gunsoy, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 8, 2020
Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and GermanyHannah B Lewis, Melanie Schroeder, Necdet B Gunsoy, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 17, 2017
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL studyFrank C Albers, Hana Müllerová, Necdet B Gunsoy, et al.
The Lancet. Respiratory Medicine|May 15, 2016
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesHector G Ortega, Steven W Yancey, Bhabita Mayer, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2016
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthmaSteven W Yancey, Hector G Ortega, Oliver N Keene, et al.
Pharmacoeconomics|July 25, 2023
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical RecommendationsKumar Mukherjee, Necdet B Gunsoy, Rita M Kristy, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
Pageof 2